Skip to main content

CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.

Nature communications

Authors: Malgorzata Krajewska, Ruben Dries, Andrew V Grassetti, Sofia Dust, Yang Gao, Hao Huang, Bandana Sharma, Daniel S Day, Nicholas Kwiatkowski, Monica Pomaville, Oliver Dodd, Edmond Chipumuro, Tinghu Zhang, Arno L Greenleaf, Guo-Cheng Yuan, Nathanael S Gray, Richard A Young, Matthias Geyer, Scott A Gerber, Rani E George

Cyclin-dependent kinase 12 (CDK12) modulates transcription elongation by phosphorylating the carboxy-terminal domain of RNA polymerase II and selectively affects the expression of genes involved in the DNA damage response (DDR) and mRNA processing. Yet, the mechanisms underlying such selectivity remain unclear. Here we show that CDK12 inhibition in cancer cells lacking CDK12 mutations results in gene length-dependent elongation defects, inducing premature cleavage and polyadenylation (PCPA) and loss of expression of long (>45 kb) genes, a substantial proportion of which participate in the DDR. This early termination phenotype correlates with an increased number of intronic polyadenylation sites, a feature especially prominent among DDR genes. Phosphoproteomic analysis indicated that CDK12 directly phosphorylates pre-mRNA processing factors, including those regulating PCPA. These results support a model in which DDR genes are uniquely susceptible to CDK12 inhibition primarily due to their relatively longer lengths and lower ratios of U1 snRNP binding to intronic polyadenylation sites.

PMID: 30988284

Participating cluster members